Partners with global innovator of Citicoline, Ferrer Internacional, Spain, to make Somazina available in India
Dr Reddy’s Laboratories (DRL) has launched Somazina, the innovator brand of Citicoline in the Indian market. DRL has partnered with the global innovator of Citicoline, Ferrer Internacional, Spain, to make Somazina available in India. This product has been used for the treatment of post-stroke patients around the world.
Somazina is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries. Citicoline is a widely used neuro-protectant to help accelerate the recovery of these patients. It is used in both ischemic and haemorrhagic strokes, and provides a compelling option to physicians treating stroke patients.
Alok Sonig, Senior Vice President and Head of India Business, DRL said, “We are excited about the partnership with Ferrer and launch of Somazina which addresses significant unmet need in patients, whose quality of life gets severely compromised after having a stroke. With the launch of Somazina and our recent acquisition of Nootropil, through the UCB brands’ acquisition, we look forward to building our presence in the neurology segment and making a difference to the lives of patients who have had the misfortune to suffer a stroke.”
